What is the standard dose of Eliquis (apixaban) for post-femoral artery bypass graft prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 22, 2025 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

From the Research

The standard dose of Eliquis (apixaban) for post femoral bypass prophylaxis is typically 2.5 mg taken orally twice daily, as supported by the most recent and highest quality study available 1.

Key Considerations

  • This regimen should generally be started 12-24 hours after surgery once hemostasis has been established.
  • The recommended duration of prophylaxis is usually 10-14 days, though some patients may require extended prophylaxis for up to 35 days depending on their individual risk factors for venous thromboembolism.
  • Dose adjustment is necessary for patients with severe renal impairment (creatinine clearance 15-29 mL/min), reducing to 2.5 mg once daily.
  • Apixaban should be used cautiously in patients with other anticoagulants, antiplatelet drugs, or NSAIDs due to increased bleeding risk.

Mechanism and Monitoring

  • The medication works by selectively inhibiting Factor Xa, preventing thrombin formation and clot development.
  • Regular monitoring of the patient for signs of bleeding is essential, and the medication should be temporarily discontinued prior to invasive procedures.
  • Patients should be advised to take the medication at the same times each day and not to skip doses, as this could increase thrombosis risk.

Evidence Base

  • The study by 1 provides the most recent and highest quality evidence for the use of apixaban in post femoral bypass prophylaxis, demonstrating its efficacy and safety in preventing recurrent venous thromboembolism.
  • While other studies, such as 2, 3, 4, and 5, provide additional information on the use of apixaban in various clinical settings, the study by 1 is the most relevant and informative for guiding clinical practice in this specific context.

Related Questions

How should apixaban be initiated and dosed for stroke prevention in non‑valvular atrial fibrillation, acute deep‑vein thrombosis or pulmonary embolism, and extended secondary prevention, including dose adjustments for age ≥80 years, weight ≤60 kg, and impaired renal function?
What to do for a patient with calf pain, on Eliquis (apixaban) for a history of Deep Vein Thrombosis (DVT), who had to hold anticoagulation for 4 days due to surgery?
Can apixaban be used to treat deep vein thrombosis in an adult leukemia patient with platelet count ≥50 × 10⁹/L and creatinine clearance ≥30 mL/min, and what dosing and monitoring are recommended?
What is the recommended dosing regimen of apixaban for treatment and prophylaxis of venous thromboembolism in adults, including adjustments for age, weight, and renal function?
Can a patient eat pineapple while taking Eliquis (apixaban)?
What are the effects of combining oral prednisone and Zyrtec (cetirizine) for the treatment of allergic dermatitis?
What is the frequency of prostate cancer association with increasing proteinuria (excess protein in the urine)?
What is the treatment for contact dermatitis using oral prednisone (Pred) and Zyrtec (cetirizine)?
What is the treatment for onychomycosis caused by Aspergillus terreus?
What is the equivalent dose of trimix (triple mixture of papaverine, phentolamine, and prostaglandin E1) for 0.5 of bimix (binary mixture of papaverine and phentolamine)?
Is Diltiazem (a calcium channel blocker) associated with tinnitus (ringing in the ears)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.